Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

D2763

Sigma-Aldrich

Dihydroergotamine methanesulfonate salt

powder

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C33H37N5O5 · CH4O3S
CAS Number:
Molecular Weight:
679.78
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

form

powder

color

white

solubility

methanol: 21 mg/mL
45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 5.45 mg/mL
H2O: insoluble

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1C[C@H](CN2C)C(=O)N[C@]5(C)O[C@]6(O)N([C@@H](Cc7ccccc7)C(=O)N8CCC[C@@]68[H])C5=O)c34

InChI

1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1

Inchi Key

ADYPXRFPBQGGAH-WVVAGBSPSA-N

Gene Information

human ... DRD2(1813)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Agonist at vascular serotonin receptors; partial agonist at α-adrenergic and dopamine D2 receptors; vasoconstrictor.
Vascular serotonin receptor agonist; vasoconstrictor.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shashidhar Kori et al.
Clinical therapeutics, 34(9), 1920-1928 (2012-08-25)
MAP0004 is an orally inhaled investigational drug containing dihydroergotamine (DHE). Although DHE has been used for 60 years with no reported cardiac arrhythmias, a thorough QT study had not previously been performed with DHE. The objective of this study was
D Kellerman et al.
Cephalalgia : an international journal of headache, 32(2), 150-158 (2011-12-17)
Dihydroergotamine (DHE), a proven migraine treatment, currently has product labeling warning against concomitant use of CYP3A4 inhibitors because of potential drug interactions. However, no reported studies of such interactions with DHE administered by any route are available. The pharmacokinetics (PK)
Bruno A Marichal-Cancino et al.
European journal of pharmacology, 692(1-3), 69-77 (2012-07-31)
It has been suggested that during a migraine attack trigeminal nerves release calcitonin gene-related peptide (CGRP), producing central nociception and vasodilatation of cranial arteries, including the extracranial branches of the external carotid artery. Since trigeminal inhibition may prevent this vasodilatation
Nancy E Kelley et al.
Headache, 52(1), 114-128 (2012-01-04)
To review and analyze published reports on the acute treatment of migraine headache with triptans, dihydroergotamine (DHE), and magnesium in emergency department, urgent care, and headache clinic settings. MEDLINE was searched using the terms "migraine" and "emergency," and "therapy" or
Abraham J Nagy et al.
Neurology, 77(20), 1827-1832 (2011-11-04)
To determine dosing and side effects of dihydroergotamine as they affect outcomes in primary headache disorders. We audited our use of dihydroergotamine for inpatient management of disabling primary headache, focusing on the commonly treated problems. Of patients interviewed, 114 had

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service